BioLineRx (BLRX) Change in Account Payables (2014 - 2026)
BioLineRx (BLRX) posted quarterly Change in Account Payables of $711000.0 for Q4 2024, down 77.07% year-over-year from $3.1 million in Q1 2024, and up 221.33% quarter-over-quarter from -$586000.0 in Q3 2024.
Powered by 
Analysis
BioLineRx (BLRX) Change in Account Payables (2014 - 2026) Analysis & Trends
BioLineRx's Change in Account Payables history runs 11 years deep, the most recent figure standing at $711000.0 for Q4 2024.
- In Q4 2024, Change in Account Payables fell 77.07% year-over-year to $711000.0; the TTM figure through Dec 2024 stood at -$5.5 million (down 199.93% YoY), while the FY2025 annual figure was -$3.5 million, up 36.86% from the prior year.
- Change in Account Payables for Q4 2024 stood at $711000.0, up from -$586000.0 in the prior quarter.
- The five-year high for Change in Account Payables was $3.1 million in Q4 2023, with the low at -$3.5 million in Q1 2024.
- The 5-year median for Change in Account Payables is $115500.0 (2020), against an average of $1666.7.
- The sharpest annual moves came in 2022 and 2024: Change in Account Payables jumped 567.56% in 2022, then plunged 1811.71% in 2024.
- BioLineRx's Change in Account Payables stood at $51000.0 in 2020, then surged by 341.18% to $225000.0 in 2021, then surged by 567.56% to $1.5 million in 2022, then surged by 106.46% to $3.1 million in 2023, then slumped by 77.07% to $711000.0 in 2024.
- Business Quant data shows BLRX's Change in Account Payables at $711000.0 in Q4 2024, -$586000.0 in Q3 2024, and -$2.1 million in Q2 2024.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Account Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.31 Bn | 131.46 Bn | 2.84 Bn | -66.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.65 Bn | 77.66 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 63.46 Bn | 58.27 Bn | 1.37 Bn | - |
| 4 | Moderna | 57.94 Bn | 52.80 Bn | 52.00 Mn | -8.00 Mn |
| 5 | Revolution Medicines | 44.05 Bn | 44.05 Bn | - | 5.03 Mn |
| 6 | BeOne Medicines | 39.96 Bn | 34.86 Bn | 1.53 Bn | 37.53 Mn |
| 7 | Alnylam Pharmaceuticals | 35.16 Bn | 31.85 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.44 Bn | 27.60 Bn | - | - |
| 9 | Insmed | 27.32 Bn | 26.16 Bn | 358.27 Mn | - |
| 10 | BioLineRx | 6.68 Bn | 6.68 Bn | 235,000.00 | -673,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -673,000.00 |
| Mar 31, 2026 | 1.94 Mn |
| Dec 31, 2025 | -428,000.00 |
| Sep 30, 2025 | -568,000.00 |
| Jun 30, 2025 | 25,000.00 |
| Mar 31, 2025 | -2.51 Mn |
| Dec 31, 2024 | 711,000.00 |
| Sep 30, 2024 | -586,000.00 |
| Jun 30, 2024 | -2.12 Mn |
| Mar 31, 2024 | -3.51 Mn |
| Dec 31, 2023 | 3.10 Mn |
| Sep 30, 2023 | 2.13 Mn |
| Jun 30, 2023 | -111,000.00 |
| Mar 31, 2023 | 394,000.00 |
| Dec 31, 2022 | 1.50 Mn |
| Sep 30, 2022 | -1.29 Mn |
| Jun 30, 2022 | 1.42 Mn |
| Mar 31, 2022 | 254,000.00 |
| Dec 31, 2021 | 225,000.00 |
| Sep 30, 2021 | 180,000.00 |